Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
Last trade$0.00
Day change$0.00 (0.00%)
Day range$0.28 – $0.295
Volume192,118
Market cap$7M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$6.78M
Price / earnings
—
Price / book
1.08×
Price / sales
—
EV / sales
—
EV / EBITDA
0.23×
Profitability
Earnings per share
-$0.38
Return on assets
-93.25%
Return on equity
-141.1%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
3×
Quick ratio
3×
Cash ratio
2.95×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$8.24M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for SNGX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$1.02M
$1.13M
$1.1M
$1.19M
$996.6K
$1.09M
$1.08M
$1.05M
Research and development
$357.01K
$974.09K
$1.78M
$2.28M
$1.58M
$1.68M
$1.94M
$2.66M
Total operating expenses
$1.38M
$2.1M
$2.88M
$3.47M
$2.58M
$2.76M
$3.03M
$3.71M
Operating income
-$1.38M
-$2.1M
-$2.88M
-$3.47M
-$2.58M
-$2.76M
-$3.03M
-$3.71M
Interest expense
$78.65K
$53.6K
$61.39K
$0
$52.35K
$69.82K
$76.03K
$0
Income before taxes
-$1.12M
-$1.99M
-$2.82M
-$3.4M
-$2.53M
-$2.7M
-$2.95M
-$3.4M
Income taxes
$0
$0
$0
-$506.62K
$0
$0
$0
-$409.11K
Net income
-$1.12M
-$1.99M
-$2.82M
-$2.9M
-$2.53M
-$2.7M
-$2.95M
-$2.99M
Net income attributable to common shareholders
-$1.12M
-$1.99M
-$2.82M
-$2.9M
-$2.53M
-$2.7M
-$2.95M
-$2.99M
EBITDA
-$1.37M
-$2.1M
-$2.88M
-$3.47M
-$2.58M
-$2.76M
-$3.03M
-$3.71M
Basic earnings per share
-$0.05
-$0.12
-$0.28
-$0.29
-$0.58
-$0.82
-$0.97
-$1.18
Diluted earnings per share
-$0.05
-$0.12
-$0.28
-$0.29
-$0.58
-$0.82
-$0.97
-$1.18
Recent news
Company coverage with links to the original publishers.
Soligenix (NASDAQ: SNGX) announced it is applying for vaccine development funding from the Coalition for Epidemic Preparedness Innovations (CEPI) for a Bundibugyo virus vaccine. The company, in collaboration with University of Hawaiʻi researchers, has developed thermostable filovirus vaccines that demonstrated up to 100% protection in non-human primates. The application leverages Soligenix's ThermoVax platform technology and addresses the ongoing Bundibugyo outbreak in the Democratic Republic of Congo and Uganda.
Soligenix shares surged 72% after announcing its ThermoVax platform can rapidly develop a vaccine for Bundibugyo virus, addressing a WHO-declared public health emergency in the Democratic Republic of Congo. The company's thermostabilized vaccine technology demonstrated 100% protection in non-human primates and has FDA Orphan Drug Designations for Sudan and Marburg viruses, providing market exclusivity and clinical trial funding.
Over 30 pharmaceutical companies are actively developing more than 30 pipeline drugs for cutaneous T-cell lymphoma (CTCL), a rare non-Hodgkin lymphoma affecting the skin. Key players including Prescient Therapeutics, Innate Pharma, and others are advancing promising therapies with various mechanisms of action through clinical trials. The market is projected to grow steadily driven by increasing adoption of targeted and immunotherapies, though limited patient populations and high treatment costs remain challenges.
Over 90 pharmaceutical companies are actively developing more than 100 pipeline psoriasis drugs across various clinical stages. Key players including Takeda, Can-Fite BioPharma, Oruka Therapeutics, and others are advancing promising therapies with novel mechanisms of action such as TYK2 inhibitors and IL-23 inhibitors. Recent developments include positive Phase III results from Alumis and Takeda, and regulatory progress from multiple companies, indicating robust innovation in the psoriasis treatment landscape.
Soligenix announced positive clinical results from a comparative study showing HyBryte™ (synthetic hypericin) demonstrated more rapid and robust treatment response compared to Valchlor® (mechlorethamine) for cutaneous T-cell lymphoma treatment. The study showed 60% of HyBryte™ patients achieved treatment success versus 20% of Valchlor® patients at 12 weeks, with HyBryte™ showing superior safety profile. The FDA awarded a $2.6 million Orphan Products Development grant to the University of Pennsylvania to support expanded treatment evaluation.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.